Methenamine Hippurate for Recurrent UTI: When Stone Prevention Needs the Opposite Urine pH
A real non-inferiority trial makes the antibiotic-sparing case. Her own chronic stone-prevention regimen makes the chemistry case against it, in exactly the same patient.
Carol B., 58, manages the produce department at a regional grocery chain, a job that has her on her feet most of a ten-hour shift and, by her own description, "drinking coffee instead of water because there's never time for a bathroom break." She has a fifteen-year history of calcium oxalate nephrolithiasis, with three symptomatic stone episodes and one lithotripsy procedure, managed for the past six years on potassium citrate to raise her urinary citrate and reduce stone recurrence — a regimen that has kept her stone-free since starting it. Her renal function has run mildly reduced for several years, attributed to the cumulative effect of recurrent stone episodes rather than any single acute injury, with a baseline eGFR around 52.
Her more recent problem is five culture-confirmed urinary tract infections over the past fourteen months, each treated acutely and now being managed with daily nitrofurantoin prophylaxis, which her primary care physician started reluctantly given how much daily antibiotic exposure that represents over a planned multi-year course. Methenamine hippurate is the guideline-recognized non-antibiotic alternative, and ALTAR — a 2022 multicenter randomized trial comparing it directly against daily antibiotic prophylaxis — found it met a strict, prespecified non-inferiority margin against exactly the therapy she's currently on. What that trial doesn't resolve for her specifically is a fact sitting in her own chart: methenamine only converts to its active antibacterial form, formaldehyde, in acidic urine, and the potassium citrate keeping her stone-free for six years works by deliberately alkalinizing hers. Her reduced renal function adds a second, separate consideration — methenamine's labeling contraindicates it in renal insufficiency without ever fixing a numeric threshold, so her eGFR of 52 falls in precisely the band where the label neither clears her nor excludes her. Which of two facts about her own chart should govern — the urine chemistry that disarms the drug, or the renal function that limits how much of it she could safely be given to compensate — is the question nobody in the room has yet asked out loud.
Weighing a trial margin against her own urine chemistry
I'd move her off daily nitrofurantoin and onto methenamine hippurate. ALTAR randomized 240 women with recurrent UTI to methenamine or daily antibiotic prophylaxis and found the non-antibiotic option met a strict, patient-and-public-defined non-inferiority margin of one UTI per person-year. Reducing her cumulative antibiotic exposure over what could be years of prophylaxis is exactly the stewardship benefit that trial was designed to test for, and it held up.
I support methenamine as a real option in general, but I want to be precise about what non-inferiority actually promised her. The trial's own absolute difference was 0.49 additional UTI episodes per person-year with methenamine, with a confidence interval running up to 0.84 — that's real for an individual patient even while the whole margin cleared the trial's own bar. "Non-inferior on average" and "this particular patient won't do worse" are different claims, and she's entitled to weigh that difference for herself before switching.
Neither of those arguments actually engages with what's sitting in her own chart. Methenamine only converts to formaldehyde, its active antibacterial form, in acidic urine — and her potassium citrate has been deliberately alkalinizing her urine for six years specifically to keep her stone-free. Starting methenamine without addressing that isn't a marginal efficacy question, it's asking a drug to work against a mechanism her own maintenance therapy is actively opposing.
Her reduced renal function is the second problem, independent of the pH question — methenamine's label contraindicates use in renal insufficiency but never says at what number, and her eGFR of 52 sits inside that unresolved band — which argues against simply raising the dose to compensate for reduced conversion efficiency.
Agreed: continue nitrofurantoin prophylaxis for now rather than switch to methenamine outright, and refer to nephrology-urology jointly to weigh whether her stone-prevention regimen could tolerate any adjustment, or whether methenamine should simply be set aside as mechanistically unsuited to her specific chemistry regardless of what ALTAR found in the trial population at large.
Not agreed: the urologist still believes methenamine should be revisited aggressively if any accommodation on the citrate regimen proves possible, given the stewardship benefit of getting her off daily antibiotics; the stewardship pharmacist and clinical pharmacologist both consider her case a genuine example of a patient for whom the population-level trial answer may simply not transfer, regardless of what accommodation nephrology is willing to make.